Thrombosis in the Patients with Coronavirus Disease 2019 (COVID-19)

Abstract

RATIONALE: The risk factors for thrombosis associated with coronavirus disease 2019 (COVID-19) are unclear. Therefore, we conducted a meta-analysis to analyze the risk factors for thrombosis in patients with COVID-19. METHODS: We searched PubMed, Embase, Web of Science, and other databases for clinical studies published from the date of database inception to October 30, 2020. RESULTS: We included 4 clinical trials with 250 participants in this meta-analysis. The proportion of thrombosis in COVID-19 patients was 57.6%. We found that the age of COVID-19 patients with thrombosis group was older than that in the non-thrombosis group (P = 0.001, I2 = 0%). The levels of infection indicators, C-reactive protein (P = 0.02, I2 = 3%) and white blood cell count (P = 0.0006, I2 = 0%) in COVID-19 patients with thrombosis group were higher than that in nonthrombosis group. The D-Dimer level in the thrombosis group was significantly higher than that in the nonthrombosis group (P < 0.00001, I2 = 4%). The levels of alanine aminotransferase (P = 0.001, I2 = 0%), aspartate aminotransferase (P = 0.002, I2 = 0%), and blood urea nitrogen (P = 0.002;I2 = 0%) in thrombosis group were significantly higher than those in non-thrombosis group. There were no significant differences in gender, comorbidities (hypertension, diabetes, coronary heart disease, etc.), and death between the thrombosis group and the non-thrombosis group. CONCLUSION: The prevalence of thrombosis in elderly patients with COVID-19 is higher. Inflammation, liver, and kidney dysfunction may be associated with thrombosis in patients with COVID-19. This study indicated that thrombosis in patients with COVID-19 is not significantly related to comorbidities.